STOCK TITAN

Yunqi discloses 2.5M STAA shares and vows to vote against Alcon deal

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Yunqi Path Capital Master Fund and affiliated entities disclose ownership of 2,500,061 shares of STAAR SURGICAL CO, representing 5.1% of 49,354,123 shares outstanding. The shares were acquired beginning in 2023 using the fund's working capital and, other than ordinary-course working capital borrowings, no borrowed funds were used. The reporting persons state they will vote against the proposed merger with Alcon, issued an open letter explaining their view that the merger process and price are deficient, and note a special meeting of stockholders is scheduled for October 23, 2025.

Positive

  • Disclosure of stake and intent provides transparency to other investors and the market
  • Shares acquired with working capital; no material leverage used to fund purchases

Negative

  • Public opposition to the Proposed Merger increases uncertainty around shareholder vote outcomes
  • Claim that the Proposed Merger undervalues the issuer could complicate deal execution and timing

Insights

TL;DR: A 5.1% institutional stake publicly opposes the Alcon merger, signalling shareholder dissent but not a blocking position.

The reporting group holds a non-controlling 5.1% stake in STAAR acquired with fund working capital. Their public opposition and open letter increase scrutiny on the merger process and price discovery, potentially influencing other shareholders or prompting further disclosures. No recent transactions in the past 60 days were reported. Financial impact depends on whether their activism persuades additional shareholders or prompts a superior offer.

TL;DR: Shareholder activism may complicate timeline but is unlikely alone to derail the Alcon transaction.

Holding 5.1%, the reporting persons have publicly opposed the Proposed Merger and reserve the right to explore strategic alternatives. Their stated concerns—process deficiencies and valuation—are common grounds in merger contests and could lead to engagement with the board or solicitation campaigns. With less than a blocking stake, material change requires coalition-building or a competing bidder.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Yunqi Path Capital Master Fund
Signature:/s/ Christopher Min Fang Wang
Name/Title:Christopher Min Fang Wang / Director
Date:09/22/2025
Yunqi Capital Limited
Signature:/s/ Christopher Min Fang Wang
Name/Title:Christopher Min Fang Wang / Director
Date:09/22/2025
Yunqi Capital Cayman Limited
Signature:/s/ Christopher Min Fang Wang
Name/Title:Christopher Min Fang Wang / Director
Date:09/22/2025
Christopher Min Fang Wang
Signature:/s/ Christopher Min Fang Wang
Name/Title:Christopher Min Fang Wang
Date:09/22/2025

FAQ

How many STAAR (STAA) shares does Yunqi report owning?

The reporting persons state they beneficially own 2,500,061 shares, representing 5.1% of 49,354,123 shares outstanding.

Will Yunqi vote for or against the Alcon merger for STAAR (STAA)?

The reporting persons state they intend to vote against the Proposed Merger and have issued an open letter explaining their opposition.

When is the STAAR special meeting to vote on the Proposed Merger?

A special meeting of stockholders is scheduled for October 23, 2025.

How were the STAAR shares purchased by Yunqi funded?

The shares were purchased using the working capital of Yunqi Path Capital Master Fund; no borrowed funds were used other than ordinary-course working capital borrowings.

Has Yunqi made other recent transactions in STAAR shares?

Except as disclosed in the filing and Exhibit C, the reporting persons state they have not effected any transactions in the past 60 days to their knowledge.
Staar Surg

NASDAQ:STAA

View STAA Stock Overview

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

939.26M
49.25M
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
MONROVIA